| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H6N4O3S |
| Molecular Weight | 214.202 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CN=C(S1)N2CCNC2=O
InChI
InChIKey=RDXLYGJSWZYTFJ-UHFFFAOYSA-N
InChI=1S/C6H6N4O3S/c11-5-7-1-2-9(5)6-8-3-4(14-6)10(12)13/h3H,1-2H2,(H,7,11)
Niridazole is used (but not officially recommended) for the treatment of schistosomiasis, dracunculiasis and tungiasis. The mode of action of niridazole is not fully understood. The major action of niridazole seems to be on the glycogen metabolism of the helminths. The drug also case structural damage to the reproductive system of female schistosomes. Another possible mechanism of action of niridazole involves the inhibition of DNA synthesis in schistosomes. It is metabolized in the liver. The most serious side effects were those connected with the nervous area (convulsion, hallucination, etc.).
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Niridazole was dissolved in dimethyl sulfoxide to obtain a solution at 1,000 ug/ml. It was further diluted in distilled water and mixed with Mueller-Hinton agar to obtain graded concentrations from 0.001 to 8 ug/ml. The minimal inhibitory concentrations of niridazole for C. fetus subsp. Jejeuni was substantially higher than that of metronidazole. The break point of niridazole may tentatively be fixed between 4 and 8 ug/ml of active drug.
ACTIVE MOIETY
